Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
NT 3 Growth Factor Receptor (TrkC Tyrosine Kise or GP145 TrkC or Neurotrophic Tyrosine Kise Receptor Type 3 or NTRK3 or EC 2.7.10.1) - Overview
NT 3 Growth Factor Receptor (TrkC Tyrosine Kise or GP145 TrkC or Neurotrophic Tyrosine Kise Receptor Type 3 or NTRK3 or EC 2.7.10.1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
NT 3 Growth Factor Receptor (TrkC Tyrosine Kise or GP145 TrkC or Neurotrophic Tyrosine Kise Receptor Type 3 or NTRK3 or EC 2.7.10.1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
NT 3 Growth Factor Receptor (TrkC Tyrosine Kise or GP145 TrkC or Neurotrophic Tyrosine Kise Receptor Type 3 or NTRK3 or EC 2.7.10.1) - Companies Involved in Therapeutics Development
AnHeart Therapeutics Inc
Bayer AG
Chugai Pharmaceutical Co Ltd
F. Hoffmann-La Roche Ltd
Handok Inc
NT 3 Growth Factor Receptor (TrkC Tyrosine Kise or GP145 TrkC or Neurotrophic Tyrosine Kise Receptor Type 3 or NTRK3 or EC 2.7.10.1) - Drug Profiles
CH-7057288 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DS-6051 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
entrectinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
larotrectinib sulfate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LM-22B10 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NOV-1601 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NT 3 Growth Factor Receptor (TrkC Tyrosine Kise or GP145 TrkC or Neurotrophic Tyrosine Kise Receptor Type 3 or NTRK3 or EC 2.7.10.1) - Dormant Products
NT 3 Growth Factor Receptor (TrkC Tyrosine Kise or GP145 TrkC or Neurotrophic Tyrosine Kise Receptor Type 3 or NTRK3 or EC 2.7.10.1) - Discontinued Products
NT 3 Growth Factor Receptor (TrkC Tyrosine Kise or GP145 TrkC or Neurotrophic Tyrosine Kise Receptor Type 3 or NTRK3 or EC 2.7.10.1) - Product Development Milestones
Featured News & Press Releases
Apr 11, 2019: Bayer announces results of sub-group alysis for Vitrakvi (larotrectinib) in patients with NTRK gene fusion-positive metastatic non-small cell lung cancer (NSCLC)
Apr 05, 2019: Handok, CMG apply for P1 trial for anticancer treatment candidate
Apr 01, 2019: Following milestone FDA Approval, MSK researchers address resistance to Larotrectinib through next-generation TRK-targeted therapeutic
Mar 15, 2019: Chugai files a New Drug Application for a ROS1/TRK inhibitor Entrectinib for the treatment of ROS1 Fusion-Positive Non-Small Cell Lung Cancer
Feb 19, 2019: FDA grants priority review to Roche’s persolised medicine entrectinib
Jan 18, 2019: Chugai files an application for expanded use of genomic mutation alysis program “FoundationOne CDx Cancer Genomic Profile”
Dec 19, 2018: Chugai Files a New Drug Application for a ROS1/TRK Inhibitor Entrectinib for the treatment of NTRK Fusion-Positive Solid Tumors
Dec 06, 2018: Chugai receives orphan drug desigtion for Entrectinib in NTRK fusion-positive solid tumors
Dec 04, 2018: BC Cancer gene discovery leads to a new drug that targets 22 cancers
Nov 27, 2018: U.S. FDA approves Larotrectinib, the first TRK inhibitor, for patients with advanced solid tumors harboring an NTRK gene fusion
Nov 26, 2018: New FDA-approved therapy targets a variety of cancers
Oct 21, 2018: Roches investigatiol persolised medicine entrectinib shrank tumours in people with NTRK fusion-positive solid tumours
Oct 21, 2018: Expanded larotrectinib data confirm findings on efficacy and safety in adult and pediatric patients with TRK fusion cancer across various tumor types
Oct 09, 2018: Bayer to showcase latest oncology research on larotrectinib at ESMO 2018 Congress
Oct 09, 2018: Loxo Oncology announces Presentation on larotrectinib at the European Society for Medical Oncology 2018 Congress
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development by Stage of Development, H1 2019
Number of Products under Development by Therapy Areas, H1 2019
Number of Products under Development by Top 10 Indications, H1 2019
Number of Products by Mechanism of Actions, H1 2019
Number of Products by Stage and Mechanism of Actions, H1 2019
Number of Products by Stage and Route of Administration, H1 2019
Number of Products by Stage and Molecule Type, H1 2019


List of Tables


Number of Products under Development by Stage of Development, H1 2019
Number of Products under Development by Therapy Areas, H1 2019
Number of Products under Development by Indications, H1 2019
Number of Products under Development by Indications, H1 2019 (Contd..1), H1 2019
Number of Products under Development by Indications, H1 2019 (Contd..2), H1 2019
Number of Products under Development by Companies, H1 2019
Products under Development by Companies, H1 2019
Products under Development by Companies, H1 2019 (Contd..1), H1 2019
Products under Development by Companies, H1 2019 (Contd..2), H1 2019
Products under Development by Companies, H1 2019 (Contd..3), H1 2019
Number of Products by Stage and Mechanism of Actions, H1 2019
Number of Products by Stage and Route of Administration, H1 2019
Number of Products by Stage and Molecule Type, H1 2019
Pipeline by AnHeart Therapeutics Inc, H1 2019
Pipeline by Bayer AG, H1 2019
Pipeline by Chugai Pharmaceutical Co Ltd, H1 2019
Pipeline by F. Hoffmann-La Roche Ltd, H1 2019
Pipeline by Handok Inc, H1 2019
Dormant Projects, H1 2019
Discontinued Products, H1 2019